SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (KCI), an Acelity company, has established a new distribution agreement with B. Braun Medical Inc. to be an exclusive provider of Prontosan® Wound Irrigation Solution for use with V.A.C. VeraFlo™ Instillation Therapy in the United States.
V.A.C. VeraFlo™ Instillation Therapy is an integrated wound therapy that couples negative pressure wound therapy (NPWT) with automated volumetric instillation of topical wound treatment solutions. The programmable soak feature allows appropriate topical wound solutions to dwell in the wound for thorough contact, facilitating dilution and solubilization of infectious material and wound debris. This dwell time is offered exclusively by V.A.C. VeraFlo™ Therapy.
“As a comprehensive supplier of advanced wound care products, we are dedicated to forming partnerships with companies such as B. Braun that provide quality products and can help us to streamline the wound management process for clinicians and patients alike,” said Ron Silverman, Senior Vice President and Chief Medical Officer, Acelity.
Based on customer feedback, the Prontosan® Wound Irrigation Solution will now be available in 1,000 mL bottles with built-in hangers and cap adaptors that provide quick and simple attachment to the V.A.C. Ulta™ Negative Pressure Wound Therapy System. The partnership also allows Prontosan® Wound Irrigation Solution to be ordered and stored alongside other V.A.C. VeraFlo™ Therapy disposables in a facility supply room instead of the pharmacy.
Recently published data by MedStar Georgetown University Hospital showed that adjunctive treatment with V.A.C. VeraFlo™ Therapy, using the V.A.C. Ulta™ Negative Pressure Wound Therapy System and the Prontosan® Wound Irrigation Solution, demonstrated a statistically significant decrease in operating room (OR) visits, time to final surgical procedure and length of stay compared to traditional V.A.C.® Negative Pressure Wound Therapy for patients with wounds that required serial surgical debridement and hospitalization.* To date, this study is the most systematic examination of the impact of V.A.C. VeraFlo™ Therapy with Prontosan® Wound Irrigation Solution in the adjunctive treatment of infected wounds in an inpatient setting. An additional randomized controlled trial utilizing V.A.C. VeraFlo™ Therapy with Prontosan® is under way and designed to further support these clinical and economic outcomes.
To learn more about V.A.C. VeraFlo™ Therapy, visit www.VACULTA.com.
Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit Acelity.com.
About B. Braun
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its “Sharing Expertise®” philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
The B.Braun Group of Companies in the U.S. includes B.Braun, B.Braun Interventional Systems, Aesculap® and CAPS®. The B.Braun U.S. headquarters is located in Bethlehem, Pennsylvania. The B.Braun Group of Companies employs more than 50,000 employees in more than 60 countries throughout the world. To learn more about B.Braun visit www.BBraunUSA.com.
*Kim PJ, Attinger CE, Steinberg JS, et al. The Impact of Negative-Pressure Wound Therapy with Instillation Compared with Standard Negative-Pressure Wound Therapy: A Retrospective, Historical, Cohort, Controlled Study. Plast. Reconstr. Surg. 2014; 133:709-716.